News stories about McKesson (NYSE:MCK) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. McKesson earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.3891218865708 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Civil-rights activist DeRay Mckesson talks justice, power at Lynchburg College (newsadvance.com)
- BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Two-Part Note Offering (reuters.com)
- How Valeant Pharmaceuticals Has Fared in 2018 (finance.yahoo.com)
- McKesson Pharmacy Systems and Creative Pharmacist Collaborate to Enhance Clinical Programs for Community … – Business Wire (press release) (businesswire.com)
- Horry County to sue opioid manufacturers, choosing a different strategy than other counties – Charleston Post Courier (postandcourier.com)
Several equities analysts have commented on MCK shares. Credit Suisse Group reissued a “sell” rating and set a $130.00 price objective on shares of McKesson in a research report on Friday, February 2nd. Mizuho set a $168.00 price objective on McKesson and gave the company a “hold” rating in a research report on Tuesday, October 24th. ValuEngine raised McKesson from a “hold” rating to a “buy” rating in a research report on Tuesday, October 31st. Zacks Investment Research raised McKesson from a “hold” rating to a “buy” rating and set a $177.00 price objective for the company in a research report on Tuesday, December 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $173.00 price objective (down previously from $178.00) on shares of McKesson in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. McKesson has an average rating of “Hold” and an average price target of $178.97.
McKesson (MCK) traded up $0.09 on Monday, hitting $149.02. The stock had a trading volume of 1,260,000 shares, compared to its average volume of 1,810,000. The company has a current ratio of 1.07, a quick ratio of 0.61 and a debt-to-equity ratio of 0.63. The stock has a market cap of $31,070.00, a price-to-earnings ratio of 6.60, a PEG ratio of 1.35 and a beta of 1.22. McKesson has a 12-month low of $133.82 and a 12-month high of $178.86.
McKesson (NYSE:MCK) last posted its quarterly earnings results on Thursday, February 1st. The company reported $3.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.92 by $0.49. The firm had revenue of $53.62 billion during the quarter, compared to analyst estimates of $51.98 billion. McKesson had a return on equity of 22.98% and a net margin of 2.34%. McKesson’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.04 EPS. equities analysts anticipate that McKesson will post 12.69 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 2nd. Stockholders of record on Thursday, March 1st will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Wednesday, February 28th. McKesson’s dividend payout ratio is presently 6.02%.
In other news, Chairman John H. Hammergren sold 65,000 shares of McKesson stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $160.00, for a total value of $10,400,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “McKesson (MCK) Receiving Somewhat Favorable Media Coverage, Report Finds” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/02/12/mckesson-mck-receiving-somewhat-favorable-media-coverage-report-finds.html.
McKesson Company Profile
McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.